New Radiopharmaceuticals in Clinical Study
[68Ga]Ga-PSMA-093 (P16-093)and [18F]F-PSMA-093(P16-093) are next-generation prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals developed for the imaging of prostate cancer. These PET tracers leverage gallium-68 (68Ga) and fluorine-18 (18F) to provide high-sensitivity detection of PSMA-expressing tumors, aiding in prostate cancer diagnosis, staging, and treatment planning.
[68Ga]Ga-P15-041 (also referred to as [68Ga]Ga-HBED-CC-BP) and [177Lu]Lu-P15-073 are novel bisphosphonate-containing radiopharmaceuticals developed for imaging and therapy of bone metastases. These agents leverage the strong bone-binding properties of bisphosphonates and the advantages of gallium-68 (68Ga) and lutetium-177 (177Lu) for precise diagnosis and targeted radioligand therapy (RLT) in cancer patients with bone metastases.
- [18F]F-D3FSP (also known as 18F-P16-129 or 18F-D3-AV45) is a novel fluorine-18 labeled PET imaging agent designed for improved detection of β-amyloid plaques.
- As a next-generation derivative of [18F]AV-45 (Florbetapir), [18F]F-D3FSP incorporates strategic deuterium substitution, which enhances its metabolic stability and reduces defluorination, leading to a higher signal-to-noise ratio. These improvements are expected to enhance diagnostic accuracy, particularly in early-stage AD detection.
[18F]D6-FP-DTBZ 代表了VMAT2 PET 成像的突破，提供了更高的准确性、更好的药代动力学和更广泛的临床适用性，可用于早期诊断、疾病监测和治疗评估。
- SERT plays a crucial role in regulating serotonin levels in the brain and is a key target in neuropsychiatric and neurodegenerative disorders. [18F]-FPBM2, a novel fluorine-18-labeled radiotracer developed for positron emission tomography (PET) imaging of the serotonin transporter (SERT), provides a non-invasive method for visualizing and quantifying SERT distribution in vivo, aiding in the study of psychiatric conditions such as depression, anxiety, and obsessive-compulsive disorder (OCD), as well as neurodegenerative diseases like Parkinson’s and Alzheimer’s disease.
- With its high specificity for SERT and favorable pharmacokinetics, [18F]-FPBM2 offers potential applications in clinical diagnostics, drug development, and therapeutic monitoring, making it a valuable tool in both research and medical practice.
-
[18F]-FPBM2 是一种应用前景广阔的 SERT PET 成像剂，具有推动神经精神和神经退行性疾病研究的巨大潜力。其高选择性、良好的药代动力学和广泛的应用使其成为临床和临床前研究的宝贵工具。
